Diethylcarbamazine Reduces Chronic Inflammation and Fibrosis in Carbon Tetrachloride- (CCl 4 -) Induced Liver Injury in Mice.

Mediators of inflammation

PubMedID: 25374445

Rocha SW, de França ME, Rodrigues GB, Barbosa KP, Nunes AK, Pastor AF, Oliveira AG, Oliveira WH, Luna RL, Peixoto CA. Diethylcarbamazine Reduces Chronic Inflammation and Fibrosis in Carbon Tetrachloride- (CCl 4 -) Induced Liver Injury in Mice. Mediators Inflamm. 2014;2014696383.
This study investigated the anti-inflammatory effects of DEC on the CCl4-induced hepatotoxicity in C57BL/6 mice. Chronic inflammation was induced by i.p. administration of CCl4 0.5?µL/g of body weight through two injections a week for 6 weeks. DEC (50?mg/kg) was administered by gavage for 12 days before finishing the CCl4 induction. Histological analyses of the DEC-treated group exhibited reduced inflammatory process and prevented liver necrosis and fibrosis. Immunohistochemical and immunofluorescence analyses of the DEC-treated group showed reduced COX-2, IL1ß, MDA, TGF-ß, and aSMA immunopositivity, besides exhibiting decreased IL1ß, COX-2, NF?B, IFN?, and TGFß expressions in the western blot analysis. The DEC group enhanced significantly the IL-10 expression. The reduction of hepatic injury in the DEC-treated group was confirmed by the COX-2 and iNOS mRNA expression levels. Based on the results of the present study, DEC can be used as a potential anti-inflammatory drug for chronic hepatic inflammation.